A new study published in the journal of Respiratory Medicine showed that patients with type 2 inflammation and chronic ...

Second Phase 3 Clinical Trial Again Shows Dupilumab Lessens Disease in COPD Patients With Type 2 Inflammation May 20, 2024 — Chronic obstructive pulmonary disease patients with type 2 ...

Reuters Health Information, May 22, 2023 ATS 2023 Dupilumab Curbs Acute COPD Exacerbations Patients treated with dupilumab for COPD also showed significant improvements in lung function at 12 and ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Most studies on COPD focus on an older cohort of participants, typically those 60 and older. By enrolling younger participants who are at risk of COPD, we hope to determine why some smokers ...

Researchers are exploring how small airway abnormalities in younger smokers could help identify who is at risk of developing COPD and establish how the chronic lung disease progresses. The article ...

Due to this, lung problems are increasing day by day, which is emerging in the form of Chronic Obstructive Pulmonary Disease (COPD). It becomes difficult to breathe in this problem. It mainly ...